Registry for patients with pulmonary hypertension and their treatment outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The COMPERA registry collects data on patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) who have recently started treatment. It aims to document patient demographics, clinical outcomes, and the effectiveness of various treatment strategies in routine clinical practice. The registry employs high-quality standards, including automated data checks and monitoring, to ensure reliable information. It also allows participating centers to compare their results with others, contributing to quality assurance and identifying evolving research needs in the PAH community.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All age groups (amendment dated 1 June 2013)
* Written informed consent
* Pulmonary hypertension (PH) of either

  * PAH: idiopathic form (IPAH) or
  * PAH associated with connective tissue diseases (PAH-CTD), with congenital heart defects (PAH-CHD), with HIV infection (PAH-HIV), or the portopulmonary form
  * Chronic thromboembolic PH (CTEPH)
  * PH in left heart diseases (with isolated diastolic dysfunction; with systolic dysfunction, other)
  * PH in pulmonary disease (chronic obstructive pulmonary disease; interstitial fibrosis, etc.)
  * "Relative PH" in CHD after cavopulmonary anastomosis or Fontan-type surgery, even without the classical pulmonary pressure criteria of PH.
* Newly initiated (i.e. a maximum of 3 months before documentation for the first time) therapy with endothelin receptor antagonists (ERA), phoshodiesterase-5 (PDE-5) inhibitors, soluble guanylate cyclase (sGC) stimulators or prostacyclins in mono- or combination therapy.

Exceptions: PAH-CHD patients can be included on maintenance or newly initiated PAH therapy (3-month rule dose not apply).

PAH-CHD patients with severe pulmonary vascular disease (e.g. Eisenmenger physiology) irrespective of treatment with any PAH drugs are eligible for inclusion, too.

Exclusion Criteria:

* Patients on maintenance therapy, i.e. previous treatment with any ERA/ PDE-5 inhibitor/prostacyclin/sGC stimulator drug longer than 3 months before documentation for the first time (exception: PAH-CHD patients).

Where it's running

• Dept. of Pneumology, University
  Leuven, Belgium Recruiting
• DRK-Klinikum Köpenick
  Berlin, Germany Recruiting
• Lung Centre, University of Giessen
  Giessen, Germany Recruiting
• Department of Pulmology; Hannover Medical School
  Hanover, Germany Recruiting
• German Heart Centre
  Munich, Germany Recruiting
• Department of Cardiovascular and Respiratory Sciences, University La Sapienza
  Rome, Italy Recruiting

Study contacts

• Principal investigator: Marius M Hoeper, MD, PhD — Department of Pulmonology, Medical School Hannover, Germany
• Study coordinator: David Pittrow, MD, PhD
• Email: david.pittrow@mailbox.tu-dresden.de
• Phone: +498152

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sleep problems in PAH patients: how sleep breathing relates to PAH outcomes

  This study tests how sleep-disordered breathing and nocturnal oxygen changes relate to outcomes in adults with pulmonary arterial hypertension.

  Recruiting Chinese Pulmonary Vascular Disease Research Group · Beijing · NCT07852403

• Impact of ambient air vs nasal liquid oxygen on exercise performance in pulmonary vascular disease

  This study tests whether using nasal liquid oxygen during a 6-minute walk test changes how far patients with PAH or CTEPH can walk compared to breathing room air.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777445

• Liquid oxygen vs ambient air during a 6-minute walk in people with pulmonary vascular disease

  This study tests whether walking with liquid oxygen at about 4 L/min helps or hinders distance walked compared with walking on room air in adults with PAH or CTEPH living in Switzerland.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777367

• Treprostinil inhalation powder for PAH patients switching from selexipag

  This study tests whether inhaled treprostinil (LIQ861) is safe and tolerable for adults with PAH who are moving from oral selexipag to inhaled therapy.

  Recruiting Phase 4 Liquidia Technologies, Inc. · Columbus, Georgia · NCT07759804

• Escalation options for PAH patients already on dual therapy

  This trial tests whether adding a prostacyclin pathway drug or increasing sildenafil dose helps PAH patients at intermediate-to-high risk who aren’t at low risk despite dual therapy.

  Recruiting Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07713914

• Vasoactive Agents in Pulmonary Hypertension Crisis

  This trial tests whether dopamine, norepinephrine, or epinephrine can safely and effectively help people with a pulmonary hypertension crisis who are in the hospital.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality and 2 other locations · NCT07667829

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.